Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
17 studies found for:    GCK
Show Display Options
Rank Status Study
1 Unknown  Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation
Condition: Type 2 Diabetes
Intervention: Drug: Liraglutide
2 Terminated
Has Results
A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2599506;   Drug: Glyburide;   Drug: Placebo
3 Completed Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Metformin;   Drug: HMS5552
4 Completed A Study of LY2608204 in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: LY2608204
5 Unknown  The Effect of ß-cell Specific Glucokinase Mutation on Glucose Homeostasis and Insulin Secretion in a MODY-2 Family
Condition: MODY-2 Diabetes
Intervention: Other: OGTT
6 Recruiting Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes
Condition: Maturity-Onset Diabetes of the Young
Intervention: Other: insulin therapy
7 Completed Add Glucokinase Activator to Target A1c
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TTP399 400 mg;   Drug: TTP399 800 mg;   Drug: Sitagliptin 100 mg;   Drug: Placebo
8 Terminated
Has Results
A Study of LY2599506 in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: LY2599506
9 Completed A Study to Compare Two Forms of LY2608204 in Healthy People
Condition: Healthy Volunteers
Interventions: Drug: LY2608204 Reference;   Drug: LY2608204 Test
10 Not yet recruiting Long-term Efficacy and Safety of HMS5552 as add-on to Metformin in T2DM
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: HMS5552;   Drug: Placebos
11 Completed Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes
Condition: Diabetes
Intervention: Other: patient care pathway
12 Suspended A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral ZYGK1 in Healthy Volunteers
Condition: Diabetes
Interventions: Drug: ZYGK1;   Drug: Placebo
13 Completed A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: ARRY-403, glucokinase activator; oral;   Drug: Placebo; oral
14 Completed A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: ARRY-403, glucokinase activator; oral;   Drug: Placebo; oral
15 Completed Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)
Condition: Maturity-onset Diabetes of the Young
Interventions: Other: Oral Glucose Tolerance Test (OGTT);   Other: iso glycaemic intravenous (iv) glucose infusion (IIGI);   Dietary Supplement: Meal test;   Other: Sitagliptin;   Other: Incretin effect on sulphonyl urea treatment
16 Completed Predisposition Genes in Monogenic Diabetes (DIAMONO)
Condition: Non Autoimmune Monogenic Diabetes
Intervention: Genetic: blood sample
17 Completed Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HMS5552;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.